Pharma's Almanac TV
PA TV
Follow the Journey
Companies We've Met
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
By The Numbers
COVID-19
189 Articles Available
1
8
Can't find what you're looking for? Try our
advanced search
.
FDA Authorization
Baricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19
PR-M11-20-022
COVID-19 Vaccine
Russia's Sputnik V COVID-19 Vaccine Is 91% Effective
PR-M11-20-023
Antibodies
Twist Bioscience Announces Positive Preclinical Data for SARS-CoV-2 Antibodies
PR-M11-20-022
COVID-19
Cue’s Molecular, Point-of-Care COVID-19 Tests Deployed to Five States in HHS and DOD Pilot Program
PR-M11-20-020
COVID-19 Testing Kit
Celltrion to Launch Both Antigen and Antibody Testing Kits in the U.S.
PR-M11-20-016
COVID-19 Vaccine
Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study
PR-M11-20-013
Fast Track
Novavax COVID-19 Vaccine Granted Fast Track Designation by U.S. FDA
PR-M11-20-008
COVID-19
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study
PR-M11-20-007
Novartis Announces Collaboration with Molecular Partners to Develop Two DARPin Therapies for Potential Use Against COVID-19
PR-M11-20-006
COVID-19 Clinical Trials
NeuroRx and Relief Therapeutics Announce Continuation of RLF-100 Trial for the Treatment of COVID-19 Respiratory Failure
PR-M11-20-005
Clinical Trials
CureVac Reports Positive Interim Phase 1 Data for its COVID-19 Vaccine Candidate, CVnCoV
PR-M11-20-002
COVID-19 Vaccine
Sanofi and GSK to Support COVAX with 200 Million Doses of COVID-19 Vaccine
PR-M10-20-18
COVID-19
Lilly Announces Agreement with U.S. Government to Supply 300,000 Vials of Investigational Neutralizing Antibody to Fight COVID-19
PR-M10-20-18
COVID-19
Aridis Pharmaceuticals Reports Positive Preclinical Efficacy Data of an Inhaled Treatment for Self-Administered COVID-19 Therapy
PR-M10-20-12
Abbott Receives FDA Emergency Use Authorization for its COVID-19 Blood Test
COVID-19 Long-Acting AntiBody (LAAB) Combination AZD7442 Rapidly Advances into Phase III Clinical Trials
PR-M10-20-07
Expansion
Centaur Biopharmaceutical Services Announces Expansion of Manufacturing Agreement with Vaxart for COVID-19 and Other Vaccine Candidates
PR-M10-20-04
Equipment
Reshoring a Nation’s API and Pharmaceutical Production
PAP-Q3-20-CL-015
Vaccine Distribution
Anticipating the Logistics of a COVID-19 Vaccination Effort
PAP-Q3-20-CL-010
Leadership
A CEO’s Perspective: Positioning a CDMO for Significant Growth
PAP-Q3-20-CL-008
Integrated CDMO
Building an Integrated and Effective CDMO from the Ground Up
PAP-Q3-20-CL-027
Decentralized Trials
Facilitating the Full Spectrum of Decentralized Trials
PAP-Q3-20-CL-009
Northern Ireland
COVID-19 and the Growing Need for Dual-Source Supply Chains
PAP-Q3-20-CL-022
Decentralized Trials
Protecting Clinical Research and Patients Through Decentralized Trial Strategies
PAP-Q3-20-CL-025
1
8
»
